Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035422 | 0.88 | PPARG (0.53) | PPARGALDH1A1MAPTMAPK10 | |
| SCHEMBL27580260 | 0.88 | PPARG (0.53) | PPARGALDH1A1MAPTMAPK10 | |
| SCHEMBL27581403 | 0.88 | PPARG (0.53) | PPARGALDH1A1MAPTMAPK10 | |
| Potassium Ion SCHEMBL6851213 | 0.87 | PPARG (0.52) | PPARGALDH1A1MAPTMAPK10HDAC1 | |
| SCHEMBL6857727 | 0.85 | PPARG (0.72) | PPARGSMN1; SMN2MAPTMAPK10F2RL3 | |
| SCHEMBL6851282 | 0.79 | ALDH1A1 (0.48) | PPARGALDH1A1SMN1; SMN2MAPTMAPK10 | |
| SCHEMBL7110258 | 0.78 | PPARG (0.45) | PPARGALDH1A1SMN1; SMN2MAPTMAPK10 | |
| SCHEMBL6858320 | 0.78 | PPARG (0.49) | PPARGALDH1A1SMN1; SMN2MAPTMAPK10 | |
| SCHEMBL6856138 | 0.77 | MAPT (0.51) | PPARGMAPTMAPK10F10 | |
| SCHEMBL6091680 | 0.77 | PPARG (0.61) | PPARGF2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | PPARG 1/4885ALDH1A1 2691/4885SMN1; SMN2 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.